Mylan CEO Regrets Patient Blowback, But Not Expanded EpiPen UseBy
CEO Heather Bresch to testify before House committee Wednesday
Congress has raised concern over price hikes of EpiPen
Mylan NV’s chief executive officer will tell Congress Wednesday that although she regrets some patients’ financial difficulties affording the EpiPen allergy shot, lawmakers should still recognize that the company has increased access to the drug.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.